
	Where results make sense

Topic: GSK

	IFPMA Health Initiatives: Participating Companies: GlaxoSmithKline
		GSK makes a vital contribution to improving healthcare in the developing world in three key areas: supplying antiretrovirals and anti-malarials at not for profit prices and vaccines at significant discounts; investing in RandD that targets diseases affecting the developing world; and community investment activities and partnerships that support better healthcare in under-served communities.
		GSK's Personal Hygiene and Sanitation Education (PHASE) is a simple handwashing education programme that is reducing diarrhoea-related disease and deaths in school children in Kenya, Nicaragua, Peru and Zambia.
		GSK is working with Yunnan Provincial Health Bureau in Kunming and the Aaron Diamond AIDS Research Centre (ADARC) on the largest HIV clinical study in China to date.
	www.ifpma.org /Health/participate/health_glaxo_part.aspx (663 words)

	GlaxoSmithKline
		GSK is a company with the size and scale to invest in the tools we need to succeed, and to drive that success going forward.
		GSK uses the scale of a huge company to reach its goal of applying science to improve patient health.
		GSK employees are each expected to strive for improvement in these key competencies and align themselves with the supportive behaviors.
	company.monster.com /glaxos (1876 words)

	GlaxoSmithKline Internet Privacy Statement - ©2005
		GSK will only collect personally identifiable data, such as your name, address, telephone number, or e-mail address, when it is voluntarily submitted to us at this website.
		GSK and/or the companies we hire and are affiliated with will use this information to comply with your requests for information and to better serve you.
		GSK recognizes that visitors to our websites are concerned about the security of their personal information, and we are committed to employing reasonable technology in order to protect the security of our website.
	consumer.gsk-chus.com /legal/privacy.aspx (829 words)

	Glaxo Sued Over Paxil Child Suicide Studies
		The lawsuit alleges GSK "engaged in repeated and persistent fraud" by concealing the negative results of five trials of Paxil on children and misrepresenting the data it did reveal.
		But GSK countered that the 1998 memo was "inconsistent with the facts" and did not reflect the company's position.
		GSK was still misrepresenting the results in letters to doctors into the middle of last year, it is alleged, as the US Food and Drug Administration was examining the issue of adolescent patients' suicidal thoughts.
	www.rense.com /general53/glaxo.htm (527 words)

	[No title]
		GSK and the Commission re- solved their differences over the inclusion or exclusion of thousands of documents, but because GSK declined to pro- duce hundreds of others -- primarily on the ground that they were shielded by the attorney-client privilege -- the Commis- sion petitioned the district court to enforce the subpoena.
		GSK asserted that all 91 documents were protected by the attorney-client privilege and that 34 of them were protected also by the privilege for attorney work product.
		GSK contends that this issue, too, was raised in a manner that deprived the Company of an opportunity to respond.
	pacer.cadc.uscourts.gov /common/opinions/200207/01-5391a.txt (2115 words)

	CommentWire by Datamonitor - GSK: defending its flagship drug (Site not responding. Last check: 2007-10-13)
		The move by GSK comes as the FDA has recently introduced changes preventing drug companies from filing multiple patents on a single drug; a tactic used in the past to extend the patent life of a drug.
		The withdrawal of three of GSK's Paxil patents is unlikely to affect the predicted revenues of Paxil, as paroxetine remains under patent until 2006 and is therefore interpreted as a gesture to comply with the new legislation.
		By giving up 3 of its less important patents, GSK may hope to improve its chances of hanging on to the ones that are delaying Apotex's generic release.
	www.commentwire.com /commwire_story.asp?commentwire_ID=4549 (475 words)

	GlaxoSmithKline (Site not responding. Last check: 2007-10-13)
		GSK is also an industry leader in the research and development of medicines and vaccines for diseases of the developing world, including an HIV/AIDS vaccine.
		GSK pioneered sustainable preferential pricing for antiretrovirals in 1997, when the company made Retrovir and Epivir available for use in mother-to-child transmission reduction programmes in the developing world at up to 75% off the global price.
		GSK continues to offer its anti-malarials at sustainable not-for-profit prices to eligible customers in the 63 countries, but the prices of these are unchanged because economies of scale have not been achieved.
	www.glaxosmithkline.fi /mediaroom/hiv2.htm (1100 words)

	Federal Court Rules in Augmentin Patent Challenge
		In the summary judgment ruling, the court ruled in GSK's favour that its patent expiring in December 2002 was valid, but ruled in Teva's favour that a GSK patent expiring in 2018 was invalid.
		GSK intends to appeal the court's ruling on the patent expiring in 2018.
		GSK awaits the judge's ruling on similar challenges to those patents made in summary judgment motions filed by Geneva.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-17-2001/0001634746&EDATE= (152 words)

	Guardian \| American patent ruling hits GSK
		But, according to trial papers, GSK believes they could drop to a fifth of their present value within weeks of cut-price rival pills flooding the market.
		GSK yesterday reiterated its forecast of high single-digit growth in earnings per share this year but added that the projection would be reassessed in the event of generic competition to Paxil.
		GSK chief executive Jean-Pierre Garnier is said to be acutely aware of the 70% collapse in sales of Prozac which occurred within a fortnight of the drug's owner, Eli Lilly, losing a critical US patent battle two years ago.
	www.guardian.co.uk /print/0,3858,4618260-103676,00.html (522 words)

	MAJOR PHARMACEUTICAL FIRM CONCEALED DRUG INFORMATION
		In fact, GSK's studies did not demonstrate that Paxil is effective in treating children and adolescents with major depressive disorder and showed the possibility of increased risk of suicidal thoughts and acts in adolescents.
		Through these and other acts, GSK deprived physicians of the information they needed to evaluate the risks and benefits of prescribing Paxil for children and adolescents and deprived these youngsters of the benefit of their physicians' professional judgment.
		GSK is based in the United Kingdom with subsidiaries in the United States and several other nations.
	www.oag.state.ny.us /press/2004/jun/jun2b_04.html (893 words)

	GSK pre Vás (Site not responding. Last check: 2007-10-13)
		GSK is a truly global player in a global industry.
		We are convinced that GSK and Government share the same objectives - getting quality healthcare to the public in an affordable way and ensuring that advances in medicine are widely available to the public.
		GSK's presence here also means that Slovakia is firmly on the map for medical and pharmaceutical research.
	www.gsk.sk /Novinky/novinka_5.html (313 words)

	law.com - Article
		GSK was also hit with a similar class action antitrust suit brought on behalf of direct purchasers, including pharmaceutical wholesalers.
		GSK argued that Chemi should have assumed that GSK's patent was invalid and that GSK was conducting the infringement action in bad faith prior to the court's judgment of invalidity.
		GSK also argued that Chemi lacks standing to bring an antitrust claim since it was not a competitor of GSK, but merely a supplier to competitors.
	www.law.com /jsp/article.jsp?id=1107783345692 (1111 words)

	Science Across the World
		GlaxoSmithKline (GSK) is one of the world's leading pharmaceutical and healthcare companies, and is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
		GSK's science education programme is part of a broad commitment to social investment that focuses on healthcare and education.
		The aims of GSK's science education programme are to develop young people's knowledge understanding and skills to enable them to make sound decisions about the science-related issues they meet in every day life, and to ensure young people are equipped and motivated to choose a career in science.
	www.scienceacross.org /index.cfm?fuseaction=content.showcontent&node=331&print=1 (122 words)

	GlaxoSmithKline Clinical Trial Register - Welcome
		GSK-sponsored trials are those for which GSK is ultimately responsible for all aspects of the study (e.g., regulatory approvals, site selection, protocol development, initiation, monitoring, safety reporting, and data analysis), even if some or all of these activities are transferred to another party.
		GSK plans to include pre-marketing trials of new formulations before launch in a major market when these trials provide important safety information that is relevant to marketed formulations.
		Additionally, GSK may be required to withhold certain trial summaries to comply with confidentiality provisions in agreements with other parties.
	ctr.gsk.co.uk /welcome.asp (669 words)

	GlaxoSmithKline: Overview
		GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
		GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
		GSK RandD is based at 24 sites in 11 countries.
	www.gsk.com /about/about.htm (284 words)

	Rick Giombetti: Paxil and Addiction (Site not responding. Last check: 2007-10-13)
		GSK has since quietly settled its appeal of the case, a major courtroom defeat for the company.
		With GSK desperately scrambling to save Paxil's remaining marketing life, it's worth asking who we are to believe in a case like this.
		That testimony was objected to by GSK's counsel and upheld by the judge in the case because it wasn't relevant to the matter of Paxil and suicide (Healy's testimony in the case can be read at my blog starting on August 27).
	www.counterpunch.org /giombetti0912.html (2507 words)

	Firm Timetable for Biota Litigation Against GSK
		Biota is suing GSK for failing to adequately support Relenza after the launch of the drug in 1999.
		At the January 31 hearing, the court ordered GSK to file their defence against Biota's Statement of Claim by April 8 and to complete full discovery by June 24, 2005.
		Biota was responsible for zanamivir, a neuraminidase inhibitor, subsequently launched by GSK as Relenza in 1999 for the treatment of influenza.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/02-01-2005/0002942327&EDATE= (265 words)

	Lotronex Tablets (alosetron hydrochloride): Questions and Answers
		Since the withdrawal of Lotronex, the FDA and GSK have received numerous emails, letters and telephone calls from patients who related how their IBS symptoms were not responsive to any therapy other than Lotronex, and how their quality of life was adversely affected by its withdrawal.
		This agreement is a way for GSK to ensure that physicians prescribing Lotronex are aware of the risks of Lotronex and the type of patients in which use of Lotronex may be appropriate.
		GSK will monitor databases to follow the use of Lotronex and survey patients to ensure they understand the risks, benefits, and warning signs for adverse events associated with the drug.
	www.fda.gov /cder/drug/infopage/lotronex/lotronex-qa_0602.htm (2569 words)

	GlaxoSmithKline Australia - 29 Dec 2004 - GSK Response to Humanitarian Disaster in Asia
		Following the humanitarian disaster unfolding as a result of the earthquake and tidal waves in Asia on 26 December, GSK will be providing medicines through international humanitarian relief agencies.
		GSK has a tried and tested process where supplies of our antibiotics are already in the warehouses of our non-profit partners so they can get them to the disaster situations quickly.
		GSK Australia has been in contact with OPAL Australia* to offer support in the provision of much needed medicines.
	www.gsk.com.au /gskinternet/publishing.nsf/Content/29Dec04-GSKResponsetoHumanitarianDisasterinAsia (224 words)

	Working at GlaxoSmithKline New Zealand
		GSK is one of only two companies that have rated in the top 20 companies in the Unlimited Magazine's "Best Places to Work" survey for each of the three years the survey has been run in New Zealand.
		GSK is an exciting organisation, which offers a variety of career opportunities.
		GSK welcomes the talent of people from diverse backgrounds to provide the expertise, dedication, and imagination to propel us toward a prosperous future.
	www.gsk.co.nz /vacancy_page.asp?PageID=15 (389 words)

	Internet Privacy Policy (Site not responding. Last check: 2007-10-13)
		GSK collects health related data and personally identifiable information such as name, address, telephone number, e-mail address or other information only when it is voluntarily submitted to us on this site.
		GSK also collects non-personally identifiable information in aggregate form to track data such as the total number of visits to our web sites, the number of visitors to each page of our web sites, and the domain names of our visitors' internet service providers.
		GSK has security measures in place to attempt to protect against the loss, misuse and alteration of your user data under our control.
	www.csib.co.uk /csib/privacy.html (929 words)

	Main Frame in Sections
		Prior to beginning work, contractors and their safety manager or designee must attend a pre-work safety conference with GSK to review procedures, forms, record keeping and reporting, and to ensure a clear understanding of the safety program relevant to the work to be performed.
		GSK also reserves the right to dictate safety standards during the course of a contract as necessary in the interest of safety.
		The GSK representative will be notified when an individual does not pass the background check and arrangements will be made to remove the individual from GSK premises.
	ussupplierdiversity.gsk.com /safetymanual/frmain01.htm (16358 words)

	SETTLEMENT SETS NEW STANDARD FOR RELEASE OF DRUG INFORMATION
		Specifically, GSK conducted at least five studies on the use of Paxil in children and adolescents but only released one of these studies, which showed mixed results on efficacy.
		GSK expects to post summaries of clinical studies completed prior to the date of the agreement between now and December 31, 2005.
		As part of the settlement, GSK has also agreed to ensure that all Medical Information Letters and other communications it provides to doctors concerning off-label use of Paxil and other drugs will fairly and accurately reflect the safety and efficacy data from clinical studies concerning off-label use.
	www.oag.state.ny.us /press/2004/aug/aug26a_04.html (629 words)

	Orenburg's Board M.I.T. Delivers Sales Force Intelligence and Analytic Planning Applications for GlaxoSmithKline (GSK) (Site not responding. Last check: 2007-10-13)
		BACKGROUND: GlaxoSmithKline (GSK) is one of the world's leading research-based pharmaceutical companies, with a powerful combination of skills and resources that provide a platform for delivering strong growth in today's rapidly changing healthcare environment.
		Headquartered in the UK, with operations based in the U.S., GSK is one of the industry leaders, with an estimated seven percent of the world's pharmaceutical market.
		GSK has more than 100,000 employees worldwide, with more than 40,000 in sales and marketing - the largest sales force in the industry.
	www.dmreview.com /master.cfm?NavID=194&EdID=5423 (789 words)

	Paxil litigation update (Site not responding. Last check: 2007-10-13)
		On October 10, 2002, Judge Pfaelzer reconsidered her preliminary injunction order and reversed her ruling based, in part, on the FDA’s representations to the Court that it had given GSK permission to run the ads and did not believe the advertisements were misleading.
		GSK also continues to make statements such as “in most instances” withdrawal effects are simply “relapse.” (Glamour Magazine, April 2003.) This is entirely inconsistent with the Paxil label in Switzerland, which states: “Discontinuation of Seroxat may lead to discontinuation symptoms.
		Although GSK was required by the FDA to strengthen its warning about Paxil withdrawal in December 2001, Plaintiffs allege that it remains inadequate.
	www.baumhedlundlaw.com /Paxil/paxilupdate.htm (1832 words)

	GlaxoSmithKline Australia - GSK POPPY
		GSK supplies 25% of the world's medicinal opiate needs from poppies grown by farmers in Tasmania.
		Each year, GSK contracts approximately 800 farmers to grow nearly 10,000 hectares of poppy crop.
		The opiates are extracted from the poppies at our factory in Port Fairy, Victoria and are used in a range of pharmacy and prescription medicines worldwide.
	www.gskpoppy.com (290 words)

Try your search on: Qwika (all wikis)